IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
25.54
-0.32 (-1.24%)
Nov 20, 2024, 4:00 PM EST - Market closed
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $3.92M in the twelve months ending September 30, 2024, down -83.30% year-over-year. In the year 2023, IDEAYA Biosciences had annual revenue of $23.39M, down -54.08%.
Revenue (ttm)
$3.92M
Revenue Growth
-83.30%
P/S Ratio
n/a
Revenue / Employee
$31,629
Employees
124
Market Cap
2.21B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Alignment Healthcare | 2.47B |
CONMED | 1.29B |
iRhythm Technologies | 560.03M |
UFP Technologies | 461.85M |
LeMaitre Vascular | 213.03M |
Wave Life Sciences | 53.61M |
Arrowhead Pharmaceuticals | 19.65M |
Centessa Pharmaceuticals | 6.85M |
IDYA News
- 3 days ago - IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer - PRNewsWire
- 9 days ago - IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day - PRNewsWire
- 10 days ago - IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - PRNewsWire
- 10 days ago - Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise - Business Wire
- 17 days ago - IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PRNewsWire
- 20 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 24 days ago - IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - PRNewsWire
- 27 days ago - IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - PRNewsWire